Nuclera moving 100 staff to new Cambridge headquarters
Nuclera, the Cambridge biotech business which is revolutionising the way proteins are made, has triggered a new phase of its global scale-up by agreeing to take space in a new headquarters building.
The company has taken a pre-let on all 31,248 sq ft of Mortlock House at Vision Park on a 10-year lease to establish its new global HQ.
The building was recently acquired by fast growing asset and development manager Lateral which is broadening its life science sector drive and focus.
The deal will see more than 100 of Nuclera’s employees move in later this year. It is currently based at Cambridge Science Park and is shortlisted in the current Business Weekly Awards. The company has outgrown its existing space.
Nuclera was founded by four PhD students at the University of Cambridge and has expanded rapidly across two continents to deliver on its founders’ vision to make proteins accessible to researchers through their eProtein™ bioprinter.
Using a streamlined combination of cutting-edge technologies in a deployable benchtop platform, Nuclera is able to provide consistent protein expression, characterisation, and purification workflows to its customers.
In July, Nuclera raised an extra $15.5 million in Series B financing to bring its haul to date to $58m.
Its recent growth and blueprint for the future has spurred the move to Mortlock House – renamed One Vision Park – for greater space and flexibility for its unique lab-based work. Purchased in a joint venture with Amazon Capital earlier this year, Lateral’s Mortlock House is the first life science sector purchase of Amazon Property’s new £250 million fund.
It follows Lateral’s recent acquisition of a major redevelopment site adjacent to the Royal London Hospital in Whitechapel’s emerging life sciences cluster. Rob Beacroft, director at Lateral says: “Our unique focus on delivering service-led lab spaces for a diverse range of occupiers is putting us front of mind for innovative companies like Nuclera.
“Lateral, like Nuclera, is a dynamic, forward-thinking business and this allowed the bespoke deal to complete within a matter of weeks. We are delighted Nuclera has chosen to move its market-leading technology and research to Mortlock House and look forward to announcing further strategic acquisitions over the coming months as we progressively increase our life sciences portfolio.”
Nuclera co-founder and CEO Michael Chen said: “The scale of our work and team is expanding at pace. Following our recent Series B raise we have secured top talent across key positions and are rapidly progressing in our mission to make proteins accessible via game-changing technology.
“We believe Lateral’s unique lab space focus mirrors our own ambition for better service and innovation in this sector.”
Lateral is fast becoming one of the major players in the life sciences space having also asset managed and sold Trinity House in Oxford earlier this year at a record price to Breakthrough Properties; in addition to its recent acquisitions in Whitechapel and Cambridge it has several other sites and transactions ongoing.
• Paddy Shipp of JLL and Mark Levine of SMB advised Lateral, and Lauren Fendick, Lucy Graham, Rebecca Miller, Emma Coates and David Quinlan of Taylor Wessing acted for Nuclera in the pre-let transaction.